For the second quarter (end-June 30, 2021), the company reported revenue of $8.3 million. During the second quarter of 2020, revenue was $11.1 million. The year-over-year decline is due to a shipment of 150 MX908 handheld devices to one customer in the second quarter of 2020, according to the company.

Gross profit was $4.4 million for the second quarter of 2021 compared to $6.4 million for the same period in 2020. Product and service gross margin was 53% in the second quarter of 2021 compared to 58% for the corresponding prior year period.

For 2021, the company changed its expected revenue forecast to $40 million to $43 million. Previously, it was projected to be between $38 million and $40 million.

908 Devices adds data insights partners for Rebel system
908 Devices announced two data analysis partnerships to integrate systems with its Rebel at-line fresh and spent cell media analyzer for bioprocess labs:...

908 Devices, Bio-Techne partner on protein characterization workflow
908 Devices and Bio-Techne are collaborating to develop an extended workflow solution for protein characterization.

Sciex, 908 Devices launch biotherapeutics characterization platform
Sciex and 908 Devices have made the ZipChip platform for Sciex mass spectrometers available to the public. This platform expands mass spectrometers from...